Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

The requested reference [e309adb24a666bf68b21ef498fd949ef65fee159] no longer exists in our database. It has been replaced by the current reference: [28fbdc530347fcd34b628651d6327d3fe3c5278d]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.
Epistemonikos ID: 0dce019ba4bc5e2c1477cd045933893792a25438
First added on: Jun 10, 2019